Compare M & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | M | ABVX |
|---|---|---|
| Founded | 1830 | 2013 |
| Country | United States | France |
| Employees | N/A | 69 |
| Industry | Department/Specialty Retail Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.2B |
| IPO Year | 2002 | N/A |
| Metric | M | ABVX |
|---|---|---|
| Price | $25.28 | $99.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $20.09 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 7.2M | 2.3M |
| Earning Date | 05-27-2026 | 03-23-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ 12.08 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $22,621,000,000.00 | N/A |
| Revenue This Year | N/A | $52.14 |
| Revenue Next Year | N/A | $4,132.27 |
| P/E Ratio | $108.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.99 | $5.88 |
| 52 Week High | $25.65 | $148.83 |
| Indicator | M | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 43.56 |
| Support Level | $16.74 | $87.60 |
| Resistance Level | N/A | $131.50 |
| Average True Range (ATR) | 1.09 | 7.76 |
| MACD | 0.32 | -1.02 |
| Stochastic Oscillator | 93.12 | 45.14 |
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.